Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director | August 20, 2024 | August 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date August 20, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2034-08-20 | Direct | 150,000 |
Reported balance
After 2024-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-20 · Grant · Acquired 150,000 · Balance 150,000 F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2024 Filed Aug 22, 2024 21:56 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001493152-24-033618 · ownership.xml · derivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:15 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-23-044419 · doc4.xml · derivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2025 or January 15, 2025. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:16 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-22-052210 · doc4.xml · derivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-09-30 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:13 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 300,000 | $0.15 | $45,000.00 |
DisclosureSEC source: 0001209191-22-042557 · doc4.xml · nonDerivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 F1 · kind: This transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors. Read SEC document |
| June 18, 2021 Filed Jun 23, 2021 00:14 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042590 · doc4.xml · derivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:06 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-20-030646 · doc4.xml · derivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2021 or January 15, 2021 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022. Read SEC document |
| March 09, 2020 Filed Mar 12, 2020 21:55 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 179,311 | $0.29 | $52,000.19 |
DisclosureSEC source: 0001209191-20-018605 · doc4.xml · nonDerivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 F1 · kind: This transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:26 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001209191-19-052409 · doc4.xml · derivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-10-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2021 or January 15, 2021. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:03 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 100,000 | $0.35 | $35,000.00 |
DisclosureSEC source: 0001209191-19-029434 · doc4.xml · nonDerivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Read SEC document |
| May 09, 2019 Filed Jun 25, 2019 21:21 UTC Amendment | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 120,689 | $0.29 | $34,999.81 |
DisclosureSEC source: 0001209191-19-038981 · doc4a.xml · nonDerivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,689 F1 · shares: The original Form 4 Report filed May 13, 2019 stated that the number of shares acquired was 100,000 at a price of $0.35 per share. This amendment reflects an amendment to the price per share. F1 · price: The original Form 4 Report filed May 13, 2019 stated that the number of shares acquired was 100,000 at a price of $0.35 per share. This amendment reflects an amendment to the price per share. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 23:26 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001209191-18-040506 · doc4.xml · derivative · entry 2 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-06-28 F2 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 23:26 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-040506 · doc4.xml · nonDerivative · entry 1 Chen Ivan · CIK 0001743729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). The RSUs vest and become exercisable as follows: (i) 50% of the RSUs will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019 and (ii) 50% of the RSUs will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.